Search Results 771-780 of 17156 for monoclonal antibody

1. Treating Highly Sensitized Patients on the Kidney Transplant Waiting List by Depleting Their B-cells Using Chimeric Antigen Receptor T Cells (CAR-T) - Mayo Clinic

   Any patients who received a desensitization therapy including any monoclonal antibodies, plasmapheresis, and/or splenectomy; Inability to understand and sign ...

2. A Dose Finding Study Followed by a Safety and Efficacy Study for Patients With Multiple Myeloma or Lymphoma - Mayo Clinic

   Monoclonal antibodies within 28 days; Corticosteroid administration >20 mg/day of prednisone or equivalent within 14 days; Proteasome inhibitors within 14 ...

3. Stopping Versus Continuation of Long-term Mepolizumab in Severe Eosinophilic Asthma Patients - Mayo Clinic

   Other Monoclonal Antibodies: Subjects who have received any monoclonal antibody (other than XOLAIR®) to treat inflammatory disease within 5 half-lives of Visit ...

4. COVID and Diabetes Assessment - Clinical Trials

   ... monoclonal antibody used for treatment) in 365 days prior to diagnosis ... (Patients who report COVID- status will also have SARS-CoV-2 nucleocapsid antibody ...

5. A Study of Tazemetostat in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer - Mayo Clinic

   Monoclonal antibody(ies). At least 28 days since last dose of monoclonal antibody prior to registration. Immunotherapy. At least 28 days since last dose of ...

6. A Study To Investigate The Efficacy And Safety Of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib In Adults With Relapsed/Refractory Mantle Cell Lymphoma - Mayo Clinic

   Received 1 to 5 prior lines of systemic therapy including an anti-CD20 monoclonal antibody (mAb)-based immunotherapy or chemoimmunotherapy and requiring ...

7. A Study to Assess the Effectiveness, Safety, and Drug/Body Interactions of Rovalpituzumab for Third-Line and Later Treatment of Patients with Small Cell Lung Cancer that has Returned or is Resistant to Treatment - Mayo Clinic

   ... monoclonal antibodies): 2 weeks; Immune-checkpoint inhibitors (i.e., anti-PD-1, anti-PD-L1, or anti-CTLA-4): 4 weeks; Other monoclonal antibodies, antibody ...

8. A Study of the Safety, Tolerability, and Drug/Body Interactions of C2N-8E12 in People with Progressive Supranuclear Palsy - Mayo Clinic

   ... antibody HJ8.5. We sought to determine the effects of ... monoclonal antibodies for their ability to block seeding activity present in P301S brain lysates.

9. Cellular Therapy Clinical Trials - Mayo Clinic Research

   ... antibody (ANCA) associated vasculitis using primary samples and/or patient ... Monoclonal antibodies, such as pembrolizumab, may block tumor growth in ...

10. Hepatocellular Carcinoma Clinical Trials - Mayo Clinic Research

    The purpose of this study is to assess the efficacy and safety of tiragolumab, an anti-TIGIT monoclonal antibody, when administered in combination with ...